Daniel George Wildman - 26 Nov 2025 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
01 Dec 2025, 16:44:50 UTC
Prior SEC filing
27 Aug 2025
Next SEC filing
24 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jason D. Smith, Attorney-in-Fact

Key filing fact

Daniel George Wildman filed Form 4 for UroGen Pharma Ltd. (URGN) on 01 Dec 2025.

Key facts

  • This page summarizes Daniel George Wildman's Form 4 filing for UroGen Pharma Ltd. (URGN).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 01 Dec 2025, 16:44.

Change

  • Previous filing in this sequence was filed on 27 Aug 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001952679 Primary reporting owner

Wildman Daniel George

Relationship
Director
Address
400 ALEXANDER PARK DRIVE, PRINCETON
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Signature date
01 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

URGN transaction

ordinary shares

Options Exercise

Transaction value
Shares
+2,000
Change %
Price
Shares after
2,000
Date
26 Nov 2025
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

URGN transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
$0
Shares
-2,000
Change %
-25%
Price
$0.000000
Shares after
6,000
Date
26 Nov 2025
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
2,000
Exercise price
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .